IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision combination therapies. Inspired by a few curative combination regimens in cancer and the successful drug cocktails purposely engineered in other disease areas such as cystic fibrosis and antivirals, IDRx aims to address the limitations of today’s precision cancer medicines with highly -selective, purposely -designed drug combinations to help more patients achieve prolonged, durable responses to therapy earlier in the course of their disease. Founded in 2022, IDRx’s leadership team has extensive experience in drug development, and collectively has been involved in the discovery, development and commercialization of more than 10 approved drugs.